Therapeutic efficacy of a polymyxin B-dextran 70 conjugate in experimental model of endotoxemia.
Numerous studies have suggested that lipopolysaccharide (LPS), a major component of the cell wall of gram-negative bacteria, is responsible for the initiation of gram-negative septic shock. Previously, others have designed therapeutic regimens to target the biologically active lipid A region of LPS by either neutralization of the biological properties of LPS or enhancement of clearance of this molecule. One such compound capable of neutralizing lipid A is the antibiotic polymyxin B. However, the clinical utility of polymyxin B is limited by its toxicity. We therefore covalently conjugated this antibiotic to the high-molecular-weight polysaccharide dextran 70, resulting in reduced toxicity of polymyxin B but retention of its endotoxin-neutralizing ability. The studies described in this report were designed to test the in vivo efficacy of this compound in an experimental animal model of gram-negative septic shock. Mice were administered graded doses of Escherichia coli or Pseudomonas aeruginosa along with D-galactosamine and the antibiotic imipenem. We had previously determined that antibiotic chemotherapy provides significant protection against E. coli-mediated lethality with smaller doses of bacteria; however, the antibiotic does not provide protection against larger doses of bacteria, but it is effective at killing the bacterial inoculum in vivo. Administration of the polymyxin B-dextran 70 conjugate provided significant protection when given with an antibiotic but was not effective by itself. A requirement for a pretreatment period prior to E. coli challenge was shown to depend upon the bacterial challenge dose. In other studies using this D-galactosamine sensitization model, we demonstrated that the lipid A-specific conjugate had no effect on lethality caused by staphylococcus aureus or tumor necrosis factor alpha. The results of these studies indicate that this compound is effective in preventing lethal gram-negative septic shock in mice and may be useful as a potential therapeutic agent in humans as well.
D000818:Animals; D016470:Bacteremia / Q000517:prevention & control; D003911:Dextrans / Q000627:therapeutic use*; D004195:Disease Models, Animal; D004337:Drug Carriers; D004731:Endotoxins / Q000097:blood*; D004927:Escherichia coli Infections / Q000517:prevention & control; D005260:Female; D005688:Galactosamine / Q000494:pharmacology; D015378:Imipenem / Q000494:pharmacology; D008070:Lipopolysaccharides / Q000633:toxicity; D051379:Mice; D011112:Polymyxin B / Q000627:therapeutic use*; D014115:Toxemia / Q000517:prevention & control*
D003911:Dextrans; D004337:Drug Carriers; D004731:Endotoxins; D008070:Lipopolysaccharides; D015378:Imipenem; D005688:Galactosamine; D011112:Polymyxin B